Digestive Diseases and Sciences

, Volume 57, Issue 5, pp 1336–1340 | Cite as

Evaluation of Fecal Myeloperoxidase as a Biomarker of Disease Activity and Severity in Ulcerative Colitis

  • Ibrahim Masoodi
  • Rakesh Kochhar
  • Usha Dutta
  • Chetana Vaishnavi
  • K. K. Prasad
  • Kim Vaiphei
  • Shabnum Hussain
  • Kartar Singh
Original Article



Subclinical inflammation in ulcerative colitis (UC) can predispose to relapses and biomarkers can detect mucosal inflammation.


To study the role of fecal myeloperoxidase (FMPO) in assessing disease activity and response to therapy in UC.


Patients with UC attending our hospital from July 2005 to September 2006 were studied. All patients underwent clinical, endoscopic, and histological assessment for disease extent and severity. Estimation of FMPO levels at baseline and on follow-up was carried out. Age-matched healthy controls were studied for FMPO levels.


A total of 55 patients of UC (30 males, 25 females, mean age 38.6 ± 12 years) and 54 age-matched controls (mean age 37.6 ± 13.6 years) were studied. Cases had higher median MPO levels than controls (0.42 [IQR 0.84] vs. 0.06 [IQR 0.12]); (p < 0.001). Cases with endoscopically more severe disease (Gr III & IV; n = 18) had higher median FMPO levels compared to those with milder disease (Gr II, n = 37), [0.075 (IQR 1.315) vs. 0.315 (IQR 0.813); p = 0.02]. The median MPO level in 27 patients was 0.58 [IQR 0.89] units/ml at presentation which on follow-up decreased significantly to 0.18 [IQR 0.42] units/ml (p value 0.002). However, there was no significant association between FMPO and endoscopic extent and histological scores of activity and chronicity.


Fecal MPO is an effective biomarker for assessing disease activity and response to therapy in patients with ulcerative colitis.


Ulcerative colitis Myeloperoxidase Biomarkers Relapse Follow up 


Conflict of interest



  1. 1.
    Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994;107:3–11.PubMedGoogle Scholar
  2. 2.
    Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431.PubMedCrossRefGoogle Scholar
  3. 3.
    Wagner M, Peterson CG, Ridefelt P, Sangfelt P, Carlson M. Fecal markers of inflammation used as surrogate markers for treatment outcome in relapsing inflammatory bowel disease. World J Gastroenterol. 2008;14:5584–5589.PubMedCrossRefGoogle Scholar
  4. 4.
    Silberer H, Küppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117–126.PubMedGoogle Scholar
  5. 5.
    Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci. 1997;42:394–403.PubMedCrossRefGoogle Scholar
  6. 6.
    Peterson CG, Eklund E, Taha Y, Raab Y, Carlson M. A new method for the quantification of neutrophil and eosinophil cationic proteins in feces: establishment of normal levels and clinical application in patients with inflammatory bowel disease. Am J Gastroenterol. 2002;97:1755–1762.PubMedCrossRefGoogle Scholar
  7. 7.
    Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103:162–169.PubMedCrossRefGoogle Scholar
  8. 8.
    Kayazawa M, Saitoh O, Kojima K, et al. Lactoferrin in whole gut lavage fluid as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins. Am J Gastroenterol. 2002;97:360–369.PubMedCrossRefGoogle Scholar
  9. 9.
    D’Incà R, Dal Pont E, Di Leo V, et al. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int J Colorectal Dis. 2007;22:429–437.PubMedCrossRefGoogle Scholar
  10. 10.
    Geboes K, Riddell R, Ost A, Jensfelt B, Persson T, Löfberg R. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.PubMedCrossRefGoogle Scholar
  11. 11.
    Binder V. A comparison between clinical state, macroscopic and microscopic appearances of rectal mucosa and cytologic picture of mucosal exudates in ulcerative colitis. Scand J Gastroenterol. 1970;5:625–632.Google Scholar
  12. 12.
    Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis. Gastroenterology. 1988;94:1383–1389.PubMedGoogle Scholar
  13. 13.
    Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;24(317):1625–1629.CrossRefGoogle Scholar
  14. 14.
    Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209.PubMedCrossRefGoogle Scholar
  15. 15.
    Van der Sluys Veer A, Biemond I, Verspaget HW, Lamers CB. Faecal parameters in the assessment of activity in inflammatory bowel disease. Scand J Gastroenterol. 1999;230:106–110.Google Scholar
  16. 16.
    Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol. 1994;89:S53–S65.PubMedGoogle Scholar
  17. 17.
    Saiki T. Myeloperoxidase concentrations in the stool as a new parameter of inflammatory bowel disease. Kurume Med J. 1998;45:69–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Krawisz JE, Sharon P, Stenson WF. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 1984;87:1344–1350.PubMedGoogle Scholar
  19. 19.
    Weissmann G, Smolen JE, Korchak HM. Release of inflammatory mediators from stimulated neutrophils. N Engl J Med. 1980;303:27–34.PubMedCrossRefGoogle Scholar
  20. 20.
    Sangfelt P, Carlson M, Thörn M, Lööf L, Raab Y. Neutrophil and eosinophil granule proteins as markers of response to local prednisolone treatment in distal ulcerative colitis and proctitis. Am J Gastroenterol. 2001;96:1085–1090.PubMedCrossRefGoogle Scholar
  21. 21.
    Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:707–712.PubMedCrossRefGoogle Scholar
  22. 22.
    Masoodi I, Kochhar R, Dutta U, et al. Fecal lactoferrin, myeloperoxidase and serum C-reactive are effective biomarkers in the assessment of disease activity and severity in patients with idiopathic ulcerative colitis. J Gastroenterol Hepatol. 2009;24:1768–1774.PubMedCrossRefGoogle Scholar
  23. 23.
    Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol. 2000;95:359–367.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Ibrahim Masoodi
    • 1
  • Rakesh Kochhar
    • 2
  • Usha Dutta
    • 2
  • Chetana Vaishnavi
    • 2
  • K. K. Prasad
    • 2
  • Kim Vaiphei
    • 3
  • Shabnum Hussain
    • 2
  • Kartar Singh
    • 2
  1. 1.Department of GastroenterologyKing Fahad Medical CityRiyadhSaudi Arabia
  2. 2.Department of GastroenterologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia
  3. 3.Department of PathologyPostgraduate Institute of Medical Education and ResearchChandigarhIndia

Personalised recommendations